middle.news
Prescient Secures EMA Orphan Drug Status for PTX-100 in CTCL
9:10am on Wednesday 19th of November, 2025 AEDT
•
Healthcare
Read Story
Prescient Secures EMA Orphan Drug Status for PTX-100 in CTCL
9:10am on Wednesday 19th of November, 2025 AEDT
Key Points
EMA grants Orphan Drug Designation for PTX-100 in CTCL
Provides 10 years EU market exclusivity and regulatory benefits
PTX-100 currently in Phase 2a trials for relapsed/refractory CTCL
Complements existing US FDA Orphan Drug and Fast Track status
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Prescient Therapeutics (ASX:PTX)
OPEN ARTICLE